Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Profound Medical Corp. reported revenue of $16M, up 50.7% year over year. Operating margin was -256.3% and net margin -264.4%, on a free-cash-flow margin of -238.4% with capital expenditure at 1.1% of revenue. Every figure is computed directly from PROF's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $16M | -256.3% | -264.4% |
| FY2024 | $11M | -309.6% | -260.4% |
| FY2023 | $7M | -398.0% | -393.4% |
How does PROF compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.